Researchers at Hannover Medical School (MHH) published a method to produce human immune cells in medium-sized bioreactors, converting induced pluripotent stem cells into immune-cell factories. The approach is designed for scalable disease research and therapeutic development, including weekly generation of about 40 million human macrophages. The work, published in Nature Protocols, describes bioreactor conditions intended to yield reliable macrophage outputs suited for downstream experimental and translational use. Industry impact: manufacturability and consistency remain major bottlenecks in cell therapy and immune-cell platform development; this kind of protocol-focused output can accelerate standardization for macrophage-based studies and preclinical pipelines.